Nurix Therapeutics, INC Form 4 insider transactions

Christine Ring, Chief Legal Officer of Nurix Therapeutics, reports the acquisition and disposal of common stock and restricted stock units to cover tax obligations.

Hans van Houte, CFO of Nurix Therapeutics, reports the acquisition and disposal of common stock and restricted stock units to cover tax obligations.

Director Roy D. Baynes of Nurix Therapeutics, Inc. was granted stock options to purchase 50,000 shares of common stock on March 11, 2025.

Hans van Houte, CFO of Nurix Therapeutics, sold shares of common stock on March 3, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Arthur T. Sands, CEO of Nurix Therapeutics, acquired 450,000 employee stock options on February 11, 2025, according to a Form 4 filing with the SEC.

Chief Financial Officer of Nurix Therapeutics, Hans van Houte, reports the acquisition of stock options and restricted stock units in the company.

Christine Ring, Chief Legal Officer of Nurix Therapeutics, received stock options and restricted stock units (RSUs) on February 11, 2025, according to a Form 4 filing.

Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, reports the acquisition of stock options and restricted stock units.

Christine Ring, Chief Legal Officer of Nurix Therapeutics, exercised stock options and sold a portion of the acquired shares on January 31, 2025, according to a recent SEC filing.

Christine Ring, Chief Legal Officer of Nurix Therapeutics, sold shares to cover tax obligations related to the vesting of restricted stock units.

Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, engaged in multiple stock transactions on January 30, 2025, including the vesting of restricted stock units and sales to cover tax obligations.

Nurix Therapeutics' Chief Financial Officer, Hans van Houte, executed multiple transactions involving the vesting and sale of company stock to cover tax obligations.

Christine Ring, Chief Legal Officer of Nurix Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan on January 2, 2025.

Christine Ring, Chief Legal Officer of Nurix Therapeutics, exercised stock options and sold shares on December 2, 2024, under a pre-arranged 10b5-1 trading plan.

Christine Ring, Chief Legal Officer of Nurix Therapeutics, exercised stock options and sold shares on November 4, 2024, according to a Form 4 filing with the SEC.

Christine Ring, Chief Legal Officer of Nurix Therapeutics, exercised stock options and sold shares on November 1, 2024, according to a Form 4 filing with the SEC.

Hans van Houte, CFO of Nurix Therapeutics, sold 3,546 shares of common stock on November 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Hans van Houte, CFO of Nurix Therapeutics, reports the acquisition and disposal of common stock and restricted stock units to cover tax obligations.

Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, reports the acquisition and disposal of common stock and restricted stock units to cover tax obligations.

Christine Ring, Chief Legal Officer of Nurix Therapeutics, reports the acquisition and disposal of common stock and restricted stock units to cover tax obligations.

Anil Kapur, a director of Nurix Therapeutics, acquired 50,000 stock options on October 15, 2024, according to a Form 4 filing with the SEC.

Christine Ring, Chief Legal Officer of Nurix Therapeutics, exercised stock options and sold shares on October 14, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Christine Ring, Chief Legal Officer of Nurix Therapeutics, exercised stock options and sold shares on October 1, 2024, according to a recent SEC filing.

Christine Ring, Chief Legal Officer of Nurix Therapeutics, exercised stock options and sold shares of common stock on September 3, 2024, according to a Form 4 filing with the SEC.

Christine Ring, Chief Legal Officer of Nurix Therapeutics, exercised stock options and sold shares on August 26, 2024, according to a Form 4 filing with the SEC.

Nurix Therapeutics' Chief Financial Officer, Hans van Houte, sold 20,000 shares of common stock on August 26, 2024, at a weighted average price of $25.2185 per share.

Hans van Houte, CFO of Nurix Therapeutics, reports the sale of common stock on August 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Christine Ring, Chief Legal Officer of Nurix Therapeutics, exercised stock options and sold shares on August 1, 2024, according to a Form 4 filing with the SEC.

Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, reports the acquisition and disposal of common stock and restricted stock units to cover tax obligations.

Christine Ring, Chief Legal Officer of Nurix Therapeutics, reports the acquisition and disposal of common stock and restricted stock units to cover tax obligations.